On May 27, 2025, a groundbreaking study published in Advanced Science detailed a novel extracorporeal blood purification technique aimed at combating antibiotic-resistant bacterial infections. Led by Professor Joo H. Kang and his research team at UNIST, this innovative method employs artificial clots to effectively capture and eliminate harmful bacteria from the bloodstream, potentially revolutionizing treatments for severe infections like sepsis.

How the Technique Works

The innovative device, referred to as the extracorporeal blood purification device (eCDTF), operates similarly to dialysis. By extracting infected blood from the body, this device uses artificial thrombi to adsorb bacteria before returning purified blood to the patient. The mechanism relies on the interaction between bacterial structures and adhesin receptor proteins found on the surface of the clots, which are designed to attract and trap diverse bacterial strains.

Core components of the eCDTF include:

  • Adhesin receptor proteins: These proteins, such as fibrinogen, fibronectin, plasminogen, and von Willebrand factor (vWF), bind dynamically to bacterial pili and microbial surface components.
  • Spiral structure: The device features an intricate design that enhances the contact area for bacterial margination, optimizing purification efficiency.
  • Cell-depleted thrombus (CDT): This unique feature allows for the effective adhesion of bacteria while preventing interference from cellular components.

Preclinical Success

In preclinical tests involving rats infected with methicillin-resistant Staphylococcus aureus (MRSA), the efficacy of eCDTF was underscored by its ability to:

  • Decrease blood bacterial counts and inflammatory markers significantly after just three hours of treatment.
  • Contribute to enhanced survival rates—rats treated twice with the device exhibited a remarkable 100% survival rate, while those treated once had a survival rate of approximately 33%.
  • Diminish bacterial loads in vital organs such as the liver and spleen, which are common targets for bacterial invasion.
Treatment Frequency Survival Rate
Single Treatment 33%
Double Treatment 100%

Innovative Mechanism Behind Bacterial Capture

The research team identified a significant phenomenon known as margination, which describes how different cellular components of blood interact with blood vessel walls. Professor Kang explained that similar to platelets, bacteria possess structural properties that allow them to be redirected toward vessel walls. The eCDTF was optimized to leverage this natural behavior effectively, enhancing bacterial capture rates.

“This technology can directly eliminate a wide range of pathogenic bacteria without the use of antibiotics, potentially transforming the treatment of bloodstream infections such as bacteremia and sepsis.” – Professor Joo H. Kang

Future Implications

The implications of this technology are profound, particularly in the context of rising antibiotic resistance. By minimizing the reliance on traditional antibiotics, the eCDTF device promises to offer a new therapeutic avenue for patients suffering from severe bacterial infections. Potential future developments include:

  • The adaptation of the technology for clinical use in human patients.
  • Further optimization of the device structure for improved bacterial capture.
  • Exploring the integration of this technology with existing treatment modalities for systemic infections.

Conclusion

The development of the eCDTF marks a significant advancement in the field of biomedical engineering, especially in addressing the critical public health challenge posed by antibiotic-resistant bacteria. As further research unfolds, the capabilities of this technology may pave the way for innovative treatments that can effectively manage severe infections, leading to improved patient outcomes.

References

[1] Jang, B. H., et al. (2025). Red Blood Cell‐Induced Bacterial Margination Improves Microbial Hemoadsorption on Engineered Cell‐Depleted Thrombi, Restoring Severe Bacteremia in Rats. Advanced Science, DOI: 10.1002/advs.202417498.

[2] Science X. (2025). Novel blood purification technique eliminates antibiotic-resistant bacteria via artificial clots. Retrieved from: Science X Article